DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries

Information source: Assiut University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postoperative Nausea and Vomiting

Intervention: dexamethasone (Drug); Gabapentin (Drug); Aprepitant (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Assiut University

Official(s) and/or principal investigator(s):
Hala S Abdel-Ghaffar, MD, Principal Investigator, Affiliation: Assisstant professor in Anesthesia and intensive care department, faculty of medicine, Assiut university, Egypt

Overall contact:
Hala S Abdel-Ghaffar, MD, Phone: +2 01003812011, Email: hallasaad@yahoo.com

Summary

To evaluate the efficacy of pre-empetive administration of Aprepitant, Versus Gabapentin prophylaxis for reducing the incidence of postoperative nausea and vomiting in Laproscopic gynacological surgeries.

Clinical Details

Official title: Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: incidence (%) of postoperative nausea and vomiting

Secondary outcome:

non invasive blood pressure

heart rate

side effects

Detailed description: Postoperative nausea and vomiting (PONV) is frequently encountered in the surgical recovery room. Laparoscopic surgery is one important risk factor for increased incidence of PONV. Gabapentin, an anticonvulsant with known postoperative analgesic properties, has shown some activity against PONV. Results from clinical trials evaluating the anti-emetic efficacy of gabapentin are conflicting. Aprepitant, a neurokinin-1 (NK1) receptor antagonist, blockades the central effects of substance P. Substance P is a neurotransmitter found in central areas associated with emesis such as the dorsal vagal complex and area postrema.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Female.

Criteria:

Inclusion Criteria: • ASA physical status I and II aged between 18 and 45 yrs. They undergo Laproscopic gynacological surgeries under general anesthesia. Exclusion Criteria:

- Central or peripheral neurological pathologies.

- History of drug abuse, chronic pain, or psychiatric disorders.

- Pregnant women

- Patients who took sedatives, antiemetics, or antipruritics within 24 hrs of

operation.

Locations and Contacts

Hala S Abdel-Ghaffar, MD, Phone: +2 01003812011, Email: hallasaad@yahoo.com

Hala saad Abdel-Ghaffar, Assiut, Assiut governorate 715715, Egypt; Recruiting
Additional Information

Starting date: August 2015
Last updated: August 14, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017